Sign in

CIK 0001678660

  • Non-accelerated filer
  • Smaller reporting company

Prelude Therapeutics Inc

Sign in to watch
Ticker
PRLD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
811384762
Phone
+1 302-467-1280
Business address
175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805
Former names
Prelude Therapeutics Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2020-09-29 BAKER BROS. ADVISORS LP Director Conversion · Series C Convertible Preferred Stock −382,884 0
2020-09-29 BAKER BROS. ADVISORS LP Director Conversion · Non-Voting Common Stock +382,884 5,058,149
2020-09-29 FRIEDMAN PAUL A Director Conversion +295,794 347,522
2020-09-29 FRIEDMAN PAUL A Director Conversion +152,576 500,098
2020-09-29 FRIEDMAN PAUL A Director Conversion · Series A Preferred Stock −295,794 0
2020-09-29 FRIEDMAN PAUL A Director Conversion · Series B Preferred Stock −152,576 0
2020-09-29 Bonita David P Director Conversion +8,332,779 9,250,191
2020-09-29 Bonita David P Director Conversion · Series A Preferred Stock −3,294,743 0
2020-09-29 Bonita David P Director Conversion · Series A Preferred Stock −2,196,494 0
2020-09-29 Bonita David P Director Conversion · Series B Preferred Stock −4,418,186 0
2020-09-29 Bonita David P Director Conversion · Series B Preferred Stock −2,945,458 0
2020-09-29 Bonita David P Director Conversion · Series C Preferred Stock −619,850 0
2020-09-29 Bonita David P Director Conversion · Series C Preferred Stock −413,234 0
2020-09-29 Bonita David P Director Conversion · Non-Voting Common Stock +5,555,186 5,555,186
2020-09-29 Combs Andrew EVP, Head of Chemistry Purchase +1,000 $19.00 $19K 260,380
2020-09-29 ORBIMED ADVISORS LLC Director Conversion +8,332,779 9,250,191
2020-09-29 ORBIMED ADVISORS LLC Director Conversion · Series A Preferred Stock −3,294,743 0
2020-09-29 ORBIMED ADVISORS LLC Director Conversion · Series A Prefered Stock −2,196,494 0
2020-09-29 ORBIMED ADVISORS LLC Director Conversion · Series B Preferred Stock −4,418,186 0
2020-09-29 ORBIMED ADVISORS LLC Director Conversion · Series B Preferred Stock −2,945,458 0

Page 17 of 19 · 369 trades